Normalized claim
Time: 85%
Oxygen levels maintained in the optimal range 85% of the time (vs. 47% manual).
Last evidence check: Jun 1, 2026
O2matic, a Danish medtech company, launched an AI-powered home oxygen therapy solution for patients with chronic obstructive pulmonary disorder (COPD). Built on Microsoft Azure, the system utilizes Azure IoT Hub and Microsoft Intune for device management and secure real-time data transfer. The AI algorithms automatically adjust oxygen flow based on continuous patient monitoring, keeping patient oxygen saturation at safe levels and reducing the need for hospital visits. Healthcare staff can monitor patients remotely, reducing exposure risks, particularly during the COVID-19 pandemic. Trials at Hvidovre Hospital showed that O2matic's system kept oxygen levels in the desired range 85% of the time compared to just 47% with manual treatment, leading to improved quality of life and greater patient independence.
Reported outcomes
85%
timeTime & speed
Strategic outcomes
Normalized claim
Time: 85%
Oxygen levels maintained in the optimal range 85% of the time (vs. 47% manual).
Last evidence check: Jun 1, 2026
Normalized claim
Time: 47%
Oxygen levels maintained in the optimal range 85% of the time (vs. 47% manual).
Last evidence check: Jun 1, 2026
No explicit deployment-stage evidence found.
Primary read
Showing 3 of 3
Patient oxygen saturation is continuously measured and sent via Azure IoT Hub to the cloud, where AI algorithms dynamically adjust oxygen flow. Microsoft Intune enables device management, security, and patient data sharing with hospital systems, allowing clinicians to monitor and intervene remotely.
The case's original source is still reachable.
Measures whether this deployment's public evidence persists — not whether the system is still in production.
AI-generated summary. Verify important details with the linked sources before relying on this case.
Was this useful?
Community
No published comments yet.